• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Emerging therapies for systemic lupus erythematosus - Focus on targeting interferon-alpha
【24h】

Emerging therapies for systemic lupus erythematosus - Focus on targeting interferon-alpha

机译：系统性红斑狼疮的新兴疗法-专注于靶向干扰素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Current therapies for systemic lupus erythematosus (SLE), a debilitating, potentially lethal, multifactorial systemic autoimmune disease, are limited to suppressing disease activity and are associated with multiple adverse effects. Recent advances in basic and translational sciences have elucidated a crucial role for the interferon-alpha (IFNα) pathway in the pathogenesis of this enigmatic disease. The so-called "type I interferon signature" has emerged as a major risk factor for disease activity of SLE. Multiple genes encoding for molecules within the type I interferon pathway have been associated with SLE in genome wide association studies. In addition, innate immune receptors are thought to be triggered by either endogenous and/or exogenous stimuli that lead to hypersecretion of IFNα. We review the multiple emerging treatment strategies targeting IFNα-related pathways. These include monoclonal antibodies against IFNα, anti-IFNα antibody-inducing vaccines, and inhibitors of Toll-like receptors. We also summarize the current status of these pharmaceutical agents in early clinical trials.
机译：目前用于全身性红斑狼疮（SLE）的治疗方法是一种使人衰弱，可能致死的多因素系统性自身免疫性疾病，其作用仅限于抑制疾病活动，并伴有多种不良反应。基础科学和转化科学的最新进展阐明了干扰素-α（IFNα）途径在这种神秘疾病的发病机理中的关键作用。所谓的“ I型干扰素签名”已经成为SLE疾病活动的主要危险因素。在全基因组关联研究中，编码I型干扰素途径内分子的多个基因已与SLE相关。另外，认为先天免疫受体由导致IFNα过度分泌的内源性和/或外源性刺激触发。我们审查了针对IFNα相关途径的多种新兴治疗策略。这些包括针对IFNα的单克隆抗体，抗IFNα抗体诱导疫苗以及Toll样受体的抑制剂。我们还总结了这些药物在早期临床试验中的现状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号